Clearmind Medicine Completes Treatment & Follow-up for 18 in Phase I/IIa AUD Trial
CMND sits 34% above its 52-week low of $0.595.
Summary
Clearmind Medicine announced the successful completion of treatment and follow-up for 18 participants in its ongoing Phase I/IIa clinical trial for CMND-100, its drug candidate for Alcohol Use Disorder. This milestone indicates continued positive progress in the multinational study, which aims to evaluate the safety, tolerability, pharmacokinetics, and preliminary efficacy of CMND-100. The company also noted the successful treatment of four additional participants at its Tel Aviv site, further expanding enrollment. This update follows previous news of ongoing treatment in earlier cohorts and represents a significant step forward for the micro-cap biotech, suggesting a favorable safety and tolerability profile and moving the company closer to potential efficacy readouts. Investors will be watching for further updates on trial progression and any preliminary efficacy data.
At the time of this announcement, CMND was trading at $0.80 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.7M. The 52-week trading range was $0.59 to $52.40. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.